A5002572755- Pharmaceutical studies and practices
- Cystic Fibrosis Research Advances
- Medication Adherence and Compliance
- Gastroesophageal reflux and treatments
- Helicobacter pylori-related gastroenterology studies
- Neonatal Respiratory Health Research
- Patient Safety and Medication Errors
- Respiratory and Cough-Related Research
- Pharmaceutical Practices and Patient Outcomes
- Electronic Health Records Systems
- Tracheal and airway disorders
- Clinical Nutrition and Gastroenterology
- Inhalation and Respiratory Drug Delivery
- Antibiotics Pharmacokinetics and Efficacy
- Immunodeficiency and Autoimmune Disorders
- Pediatric Pain Management Techniques
- Adrenal Hormones and Disorders
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Pediatric health and respiratory diseases
- Genomics and Rare Diseases
- Peripheral Neuropathies and Disorders
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Breastfeeding Practices and Influences
- Gastrointestinal motility and disorders
- Healthcare innovation and challenges
University Hospital Southampton NHS Foundation Trust
2010-2024
Southampton Children's Hospital
2015-2024
Boston Children's Hospital
2014
Hampton University
2010
Southampton General Hospital
2009
This is the third in a series of four papers updating European Cystic Fibrosis Society (ECFS) standards for care people with CF. paper focuses on recognising and addressing CF health issues. The guidance was produced wide stakeholder engagement, including from community, using an evidence-based framework. Authors contributed sections, summary statements which were reviewed by Delphi consultation.Monitoring treating airway infection, inflammation pulmonary exacerbations remains important,...
Cystic fibrosis (CF) has entered the era of variant-specific therapy, tailored to genetic variants in Fibrosis Transmembrane Conductance Regulator (CFTR) gene. CFTR modulators, first therapy available, have transformed management CF. The latest standards care from European CF Society (2018) did not include guidance on as modulators were becoming established a novel therapy. We produced interim guide healthcare professionals provision for people with Here we provide evidence-based covering...
Cardiovascular disease is a common comorbidity in chronic obstructive pulmonary (COPD). Yet cardiovascular and risk under diagnosed COPD often undertreated, increasing the of cardiopulmonary events. We formed Global Working Group experts to produce consensus statement detailing identification management patients with COPD. conducted virtual meetings supplemented by remote working communication. The Chairs (CPG, MB) proposed draft statement, which was further developed Group. selection final...
Abstract Introduction Elexacaftor, Tezacaftor, Ivacaftor (ETI) became available in the UK August 2020 to treat people with Cystic Fibrosis (CF) aged > 12 years. We report a real-world study of clinical outcomes young treated ETI at our CF centre within first two years its availability. Methods Participants 12-17 were identified clinic, demographic data supplemented by registry. Comprehensive outcome spanning pre- and post-initiation CFTR modulators compiled from various local sources,...
Background Whilst the prescribing of both in-patient and discharge medicines is electronic, there was no automatic notification to clinical pharmacists when a prescription ready be screened. The required member medical or nursing staff bleep their pharmacist informing them prescription's availability. This manual process led delay in screening which impacted on discharge. Prescriptions designated for pre-packed patient's own medicine use were not seen at all by pharmacist. initial intention...
Postnatal growth failure is common in preterm infants and one reason for this that nutritional care often variable suboptimal. Achieving targets nutrient intakes group of patients difficult, particularly the first few weeks life when they are reliant on parenteral nutrition (PN). <h3>Aims</h3> We aimed to improve delivery Neonatal Intensive Care Unit by provision an improved, all inclusive standardised PN supply from ready made bags lipid syringes. In addition, we reduce need bespoke...
<h3>Objective</h3> The aim of this audit was to establish if there is need for a pharmacist-led regular education programme covering the various prescribing scenarios and dose calculations required nursing staff on our child health wards. <h3>Methods</h3> Questionnaires, comprising 10 questions, were distributed approximately 25% staff, across all shift patterns bands. Nurses given 15 min during their complete questions individually without conferring afterwards; they returned anonymously...
The aim of this research was to provide clinically relevant evidence for Y-site compatibility drug infusion combinations used in the PICU. Pharmacists and clinicians regularly have interpret limited published data, particularly when more than two drugs are Y-sited. risk potential incompatibility must be balanced against that additional line insertion.
<h3>Objectives</h3> To evaluate if vancomycin injections can be successfully nebulised via the Pari LC Plus and eFlow rapid nebulisers, by measuring particle size of droplets produced, proportion concentration drug remaining in nebuliser, including calculating percentage available for inhalation, as well investigating stability during nebulisation process. <h3>Method</h3> Doses 250 mg (50 mg/ml–500 vial dissolved with 9.6 ml water injection) were both nebuliser systems. Particle...
In pediatric ambulatory care, the speed of medication infusion can have major impact on healthcare staff workload and number children able to be treated by services designed reduce inpatient length stay. many regions world, local supraregional guidelines allow ceftriaxone infusions ≥50 mg/kg in infants up 12 years age given over 10 minutes. The generic European summary product characteristics for does not state a specific time this dose range, although 1 manufacturers' United Kingdom states...
<h3>Background</h3> Prescribing errors have recently been highlighted as a significant problem; the General Medical Council commissioned study (EQUIP) in 20091 which found most common were with dosing. Whilst EQUIP focussed on adult prescribing consequences of dosing children are more harmful. In 2010, Ghaleb <i>et al</i>. Conducted across range paediatric settings London demonstrated 13% error rate.2 The pharmacy team at Southampton Children9s Hospital provided teaching doctor9s induction...
<h3>Aims</h3> To assess, using Cochrane methodology, the current pharmacological treatments for gastro-oesophageal reflux disease (GORD) Upper GI&Pancreatic Diseases group. <h3>Methods</h3> We searched RCTs in Central Register of Controlled trials, MEDLINE, EMBASE, CISCOM and ISI Science Citation Index, web science Meta-Register Trials. Handsearching references was performed including published abstracts from gastroenterology conferences over 5 years. Abstracts were reviewed relevant...